Address: IMS Poland Ltd. Sp. z o.o.
ul. Postępu 15 C
02 – 674 Warszawa,Poland
Tel: +48 22 598 03 00
Web: https://www.imspoland.com.pl/x.node?id=2537129
The demand for reliable market intelligence and accountability in global healthcare has never been greater. From researchers and payers to government agencies and pharmaceutical manufacturers, healthcare stakeholders need to better understand the role prescription drugs play in delivering high-quality, cost-effective care. At the same time, pharmaceutical companies face unprecedented competition for market share and pressures to maximize brand lifecycles, all while proving the value of their medicines.
In today’s complex healthcare marketplace, a growing set of audiences depend on IMS to yield the most accurate perspective of global market dynamics.
The offer of IMS Health in Poland includes constant monitoring of the pharmaceutical market in terms of:
– The sale and distribution of medicines and medical products for hospital and pharmacy market.
– Behavior therapy outpatient physicians.
– Promotional activities for prescription drugs.
IMS Health Consulting carries out projects to assess the effectiveness and optimizing sales teams as well as optimize the product portfolio of companies.
IMS Publications offer specialized, comprehensive and tailored to the individual orders, reports and analysis on the global pharmaceutical market.
Detailed product range and service is available for IMS clients.
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
IMS ‘lives and breathes the pharma industry’ and it is stimulating to come from other forms of consultancy to IMS. You have worked in various businesses. What motivated you to…
Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the…
Michael Kern, director general of the German Chamber of Commerce in Poland, discusses the evolving economic and business landscape in Poland and the overall impact of German companies. Furthermore, he…
Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging…
Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to…
Michael Dembinski, chief advisor of the British Polish Chamber of Commerce, discusses the important role of the chamber in driving forward Polish clinical trials and the challenges in unlocking Poland’s…
Mirosław Wysocki, national consultant in the area of Public Health, professor at the National Institute of Public Health (NIH), the research institute responsible inter alia for health promotion and disease…
Monika Constant, director general of the French-Polish Chamber of Commerce in Poland (CCIFP), discusses the evolution of the two nations’ bilateral business relationship, the benefits of conducting business in Poland,…
Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care…
Bogna Cichowska-Duma, general director of the Employers’ Association of Innovative Pharmaceutical Companies (INFARMA), the voice of 28 leading innovative companies in Poland, discusses the challenges and opportunities for doing research…
Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims…
Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction…
Wojciech Kuta, editor-in-chief of Rynek Zdrowia, a leading Polish healthcare publication, discusses the interacting dynamics of the obstacles facing Polish healthcare, as the country aims to increase healthcare spending to…
See our Cookie Privacy Policy Here
